2015 - 5 Issue

Original article

Aflibercept in the Diabetic Macular Edema Treatment

Jan Studnička ORCID

Full Text links

DOI:

Published in Czech and Slovak Ophtalmology: 2015 - 5

Published on website: 25.09.2015

Keywords: diabetic macular edema, aflibercept, ranibizumab, bevacizumab

Summary

Diabetic retinopathy is together with the diabetic macular edema the most common cause of vision loss in the working population. It is also the most common diabetic microvascular abnormality. Aflibercept is approved for the diabetic macular edema treatment, it is a recombinant fusion protein, binding VEGF A, B, and P1GF. The efficacy and safety of the treatment comparing with the laser treatment were set by VIVID-DME and VISTA–DME studies. The T DRCR.net study protocol confirmed the efficacy of aflibercept, ranibizumab, and bevacizumab in the treatment of diabetic macular edema. The best results in the whole group were obtained if using aflibercept, especially in the group of patients with worse initial visual acuity. In all three studies, the safety of intraviteraly applied aflibercept was proven. 

References

  1. Clarke, M.: Diabetic retinopathy – reasons for screening. In: Dodson, PM., Diabetic retinopathy. Oxford: Oxford University Press; 2008: 11–5.
  2. Diabetic Retinopathy Clinical Research Network, Wells, JA., Glassman, AR. et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med, 372; 2015, 13: 1193–203.
  3. Hirai, FE., Knudtson, MD., Klein, BE. et al.: Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol, 145; 2008: 700–6.
  4. Cheung, N., Wong, TJ.: Diabetic retinopathy and systemic complications. In: diabetic macular edema. Ophthalmology, 118; 2011, 4: 615–25.
  5. Korobelnik JF ., Do, DV., Schmidt-Er - furth, U. et al.: Intravitreal aflibercept for diabetic macular edema. Ophthalmology, 121; 2014, 11: 2247–54.
  6. Massin, P., Bandello, F., Garweg, JG. et al.: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care, 33; 2010, 11: 2399–405.
  7. Mitchell, P., Bandello, F., Schmidt-Er - furth, U. et al.: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for
  8. Nguyen, QD., Brown, DM., Marcus, DM. et al.: Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology, 119; 2012, 4: 789–
  9. Sosna T., Švancarová, R., Netuková, M. et al.: Nové postupy v léčbě diabetické makulopatie. Kazuistiky v diabetologii, 10; 2012: 15–22.
  10. Zander, E., Herfurth, S., Bohl, B. et al.: Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Brit J Ophthalmol, 84; 2000: 871–6.